Escitaloparm-induced paroxysmal dystonia [2]

Clinical Neuropharmacology

Volumn 30, Issue 2, 2007, Pages 124-126

  Garcia Ruiz, Pedro J ^a   Cabo, Iria ^a   Bermejo, Pablo Garcia ^a   Carnal, Pablo ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; ESCITALOPRAM;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; LETTER; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DYSTONIA; FEMALE; HUMANS;

EID: 34147219424     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000265970.57524.57     Document Type: Letter

References (29)

1. Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006;18:83-89.
2. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-1341.
3. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-131.
4. Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-175.
5. Black B, Uhde TW. Acute dystonia and fluoxetine. J Clin Psychiatry 1992;53:327.
6. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-698.
7. Arnone D, Hansen L, Kerr JS. Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care. J Psychopharmacol 2002;16:395-397.
8. Tarlaci S. Citalopram-induced jaw tremor. Clin Neurol Neurosurg 2004;107:73-75.
9. Parvin MM, Swartz CM. Dystonic rabbit syndrome from citalopram. Clin Neuropharmacol 2005;28:289-291.
10. Altindag A, Yanik M, Asoglu M. The emergence of tics during escitalopram and sertraline treatment. Int Clin Psychopharmacol 2005;20:177-178.
11. Patel OP, Simon MR. Oculogyric dystonic reaction to escitalopram with features of anaphylaxis including response to epinephrine. Int Arch Allergy Immunol 2006;140:27-29.
12. Dominguez-Moran JA, Callejo JM, Fernandez-Ruiz LC,, et al. Acute paroxysmal dystonia induced by fluoxetine. Mov Disord 2001;16:767-769.
13. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005;28:205-214.
14. Demirkian M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995;38:571-579.
15. Sethi K. Paroxysmal dyskinesias. In: Jankovic J and Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore: Williams & Wilkins, 1998: 701-709.
16. Camac A, Greene P, Khandji A. Paroxysmal kinesigenic dystonic choreoathetosis associated with a thalamic infarct. Mov Disord 1990;5:235-238.
17. Berger JR, Sheramata WA, Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol 1984;41:747-750.
18. Fontoura P, Vale J, Guimaraes J. Symptomatic paroxysmal hemidystonia due to a demyelinating subthalamic lesion. Eur Journal Neurol 2000;7:559-562.
19. Tranchant C, Bhatia KP, Marsden CD. Movement disorders in multiple sclerosis. Mov Disord 1995;10:418-423.
20. Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol 2002;89:401-420.
21. Micheli F, Fernandez Pardal M, de Arbelaiz R, et al. Paroxysmal dystonia responsive to anticholinergic drugs. Clin Neuropharmacol 1987;10:365-369.
22. Linazasoro G, Marti-Masso JF, Urtasun M, et al. Paroxysmal dystonia induced by exercise secondary to flecainide. Neurologia 1991;6:344.
23. Gay CT, Ryan SG. Paroxysmal kinesigenic dystonia after methylphenidate administration. J Child Neurol 1994;9:45-46.
24. Warner GT, McAuley JH. Alcohol-induced paroxysmal nonkinesogenic dyskinesia after pallidal hypoxic insult. Mov Disord 2003;18:455-456.
25. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997;31:1481-1489.
26. Walmeier PC, Delini-Stula AA. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1995;55:363-373.
27. Di Rocco A, Brannan T, Prikhojan A, et al. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247-251.
28. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20:277-287.
29. Mathen D, Marsden CD, Bhatia KP. Selective serotonin reuptake inhibitors-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Mov Disord 1999;14:874-876.